Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analyst consensus: "Hold" — Eight brokerages cover Inovio with a consensus Hold rating (1 sell, 3 hold, 4 buy) and an average 12‑month price target of $6.75.
• Recent results surprised to the upside as Inovio reported $0.31 EPS for the quarter versus analysts' -$0.37 estimate, but the average forecast for the current fiscal year remains a loss of -$4.23 per share; the stock trades around $1.05 with a market cap of about $72.9 million and a 52‑week range of $1.05–$2.98.
• Institutional/hedge fund ownership stands at about 26.79%, and analyst actions have been mixed — Oppenheimer reiterated an Outperform, Weiss kept a Sell, and Wall Street Zen recently upgraded the stock to Hold.

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have earned a consensus rating of "Hold" from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $6.75.

A number of equities analysts have commented on INO shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reiterated a "neutral" rating on shares of Inovio Pharmaceuticals in a report on Tuesday, December 30th. Wall Street Zen upgraded shares of Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. Finally, Oppenheimer reiterated an "outperform" rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. MCF Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals during the third quarter valued at about $26,000. SG Americas Securities LLC acquired a new position in shares of Inovio Pharmaceuticals during the third quarter valued at about $27,000. Stephens Inc. AR acquired a new position in shares of Inovio Pharmaceuticals during the third quarter valued at about $32,000. Focus Partners Wealth acquired a new position in shares of Inovio Pharmaceuticals during the third quarter valued at about $33,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 5,894 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company's stock.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.05 on Friday. The company has a market capitalization of $72.91 million, a PE ratio of -0.62 and a beta of 1.70. The company has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $1.92. Inovio Pharmaceuticals has a one year low of $1.05 and a one year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.68. On average, equities analysts predict that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.